DNA Share Price Performance
US$6.40
-0.06 (-0.93%)
46.7% undervalued intrinsic discount
US$12.00
Fair Value
Price US$6.40
AnalystHighTarget US$12.00
AnalystConsensusTarget US$10.00
AnalystLowTarget US$9.00
Fair ValueUS$12.00
Share Pricen/a
Ginkgo Bioworks Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 60 Fair Values set on narratives written by author
DNA Community Narratives
AN
Fair Value US$12 46.7% undervalued intrinsic discount
Automation And AI Expansion Will Advance Lab Markets Despite Risks
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$8.67 26.2% undervalued intrinsic discount
Cost Reductions And New Partnerships Will Shape Profit Prospects By 2026
0users have liked this narrative
0users have commented on this narrative
54users have followed this narrative
AN
Fair Value US$9 28.9% undervalued intrinsic discount
Intensifying Competition And Regulatory Burdens Will Hurt Synthetic Biology Revenue
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cost Reductions And New Partnerships Will Shape Profit Prospects By 2026
Key Takeaways Overly optimistic revenue and margin expectations face obstacles from slow sector adoption, underused lab capacity, and challenges in monetizing new AI and data offerings. Regulatory, geopolitical, and competitive pressures may limit long-term growth, especially as customer acquisition and core-product commoditization risks increase.Read more
182
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
54users have followed this narrative
AN
US$8.67
26.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
15.52%
Future PE
27.91x
Price in 2029
US$11.58
Automation And AI Expansion Will Advance Lab Markets Despite Risks
Key Takeaways Aggressive cost savings and early investments position Ginkgo for faster profitability, higher margins, and substantial operating leverage as growth areas expand. Commercialized automation platforms and entry into academic consumables market enable diversified, recurring revenue streams, while proprietary data assets unlock high-value AI partnerships.Read more
67
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$12
46.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
15.74%
Future PE
23.66x
Price in 2029
US$15.77
Intensifying Competition And Regulatory Burdens Will Hurt Synthetic Biology Revenue
Key Takeaways Reliance on project-based contracts and biosecurity funding creates revenue instability, while persistent negative cash flow limits the ability to scale and invest in growth. Intensifying competition, regulatory scrutiny, and public mistrust threaten market share and revenue realization as synthetic biology becomes more widely adopted.Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
28.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
14.2%
Future PE
29.1x
Price in 2028
US$11.49
Trending Discussion
Recently Updated Narratives
AN
DNA: Future Returns Will Hinge On Monetizing Autonomous Labs By 2026
Fair Value: US$8.67 26.2% undervalued intrinsic discount
54 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DNA: 2026 Guidance Will Anchor Sector Recovery And Support Multi-Year Upside
Fair Value: US$12 46.7% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Intensifying Competition And Regulatory Burdens Will Hurt Synthetic Biology Revenue
Fair Value: US$9 28.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ginkgo Bioworks Holdings, Inc. Key Details
About DNA
- Founded
- 2008
- Employees
- 485
- CEO
- WebsiteView website
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
